• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does H.B. Fuller (FUL) Trade Below Fair Value After New Debt?

    Simply Wall St·10/14/2026 18:16:26
    Listen to the news

    H.B. Fuller has seen its share price under pressure in recent years, even as investors focus on the cash it can generate over time. With the stock recently closing at US$50.44 and sentiment shaped by insider buying and fresh funding plans, the key question is whether that price lines up with what the business's cash flows can support.

    • Over the past 3 years, H.B. Fuller shares have declined 25.4%, which puts the spotlight firmly on whether the current valuation still reflects the cash the company is expected to produce.
    • The recent US$850m senior notes issue to help fund the Advanced Medical Solutions acquisition and refinance borrowings can reshape the timing and risk profile of future cash flows, as interest costs and integration outcomes feed through to available cash for investors.
    • If you'd rather focus on earnings, this one's for you. See why H.B. Fuller's 13.7x P/E tells a different valuation story.

    For investors, the debate is whether H.B. Fuller's current share price is justified by the intrinsic value suggested by its Discounted Cash Flow (DCF) estimate.

    If you are evaluating H.B. Fuller after a 25.4% share price decline over 3 years, it can be useful to compare it with other 32 high quality undervalued stocks.

    Does H.B. Fuller Look Undervalued on Cash Flow?

    The Discounted Cash Flow (DCF) model here projects what H.B. Fuller could generate for shareholders based on future free cash flows. On the numbers provided, the business produced last twelve month free cash flow of about $144.3 million, with forecasts pointing to higher annual free cash flow by 2028 and then a gradual step up through 2036. Those projections feed into a 2 Stage Free Cash Flow to Equity framework that assumes H.B. Fuller shifts from a stronger growth phase into a steadier pattern over time.

    The DCF estimate currently sits substantially above the share price of US$50.44, which suggests the market is assigning a heavier discount to those projected cash flows. The recent US$850 million senior notes issue to fund the Advanced Medical Solutions deal and refinance borrowings helps explain some of that gap, as investors weigh higher interest costs and integration risk against the projected long term cash generation. Find out what H.B. Fuller could be worth using our Discounted Cash Flow (DCF) estimate.

    The H.B. Fuller Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives pick up where the valuation puzzle for H.B. Fuller leaves off and explain which potential paths for future growth, margins and earnings would need to occur for the stock to be worth materially more or less than today's price. Each narrative connects its figures to a specific view on how H.B. Fuller's growth, profitability and risk profile could change over time, giving you a reference point you can revisit as new information becomes available.

    One of the top community narratives on H.B. Fuller: 26% undervalued

    "The main execution priority is integrating AMS and other medical assets while delivering the targeted manufacturing footprint reductions and conversion cost savings…"

    Discover why this Narrative puts H.B. Fuller at 26% undervalued.

    H.B. Fuller’s price is only one piece of the decision puzzle

    H.B. Fuller’s valuation story looks one way on cash flow, yet the research checks also flag specific risk signals that could tilt how you view the whole picture. Take a closer look at 1 major warning sign before settling on a valuation.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.